akayasu arteritis (TA) is a chronic vasculitis, mainly involving the aorta and its main branches such as the brachiocephalic, carotid, subclavian, vertebral and renal arteritis, as well as coronary and pulmonary arteries. 1, 2 Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have generally been used to monitor disease activity in patients on immunosuppressive therapy. There is a report that matrix metalloproteinase (MMP)-2, MMP-3, MMP-9 could be sensitive biomarkers for TA activity. We revealed that the level of PTX3 is increased even in active TA patients whose CRP is not elevated. 3 An investigation from another laboratory confirmed our observation. 4 For routine management of patients with TA using these biomarkers to estimate the activity of disease effectively, it is very important to understand the characteristics of each biomarker.
In this study, we evaluated the statistical analysis of these biomarkers for TA activity in patients diagnosed in hospital. Considering the need of prednisolone treatment for TA, we especially examined the relationship between prednisolone dose and these biomarkers to show their characteristics.
Methods

Study Patients
We screened 45 consecutive patients under 50 years of age (3 males, 42 females; age 13-49 years: average, 30.3±10.3 years) diagnosed as TA and referred to the Department of Cardiovascular Medicine, Tokyo Medical and Dental University Hospital. The TA diagnosis was based on the presence of symptoms and signs of ischemic and inflammatory large-vessel disease supported by magnetic resonance angiography (MRA). All patients fulfilled more than 3 of the 1990 American College of Rheumatology (ACR) criteria for TA classification. 5 We also diagnosed by referring to the Guideline for Management of Vasculitis Syndrome (Japanese Circulation Society 2008). 6 All patients fulfilled both sets of criteria. We excluded patients who had received stent implantation, unstable angina, or gastrointestinal tract involvement. 7- 9 We also excluded patients with giant cell arteritis according the ACR criteria. According to the patients' clinical symptoms, 28 were classified as active phase (3 males, 25 females; aged 13-47 years; average, 26.3 years) as evidenced by clinical recurrences such as progression of arterial stenosis or dilatation on MRA and carotid artery ultrasound, worsening numbness of the arms, continuous fever, arm pain with use or neck or jaw pain within 2 years before or after the blood sampling. Recurrence of the arteritis occurred before or at the time of the measurement of these biomarkers in the majority, but occurred only after the measurement in the other patients (n=4/28). These clinical signs and symptoms were usually accompanied by an elevation in
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the serum CRP level, but in some cases there was not an elevation beyond 0.5 mg/dl. Febrile patients with apparent causes such as the common cold, urinary tract infection and other infectious diseases were not recognized as having a TA recurrence. All patients in this group satisfied the National Institutes of Health (NIH) criteria for active TA disease. 10 The remaining 17 patients were categorized as inactive phase (all of them were female; age 25-49 years; average, 36.9 years) and 20 healthy subjects (all of them were female; age 19-45 years; average, 30.3 years) were registered as normal controls. Adequate informed consent was given by each participant. The study protocol was approved by the Ethics Review Board of the Tokyo Medical and Dental University Graduate School of Medicine.
Biochemical Analyses
Venous blood samples were collected into sterile tubes and the plasma and sera were immediately frozen and stored at −80°C until analyses. Circulating levels of high-sensitivity CRP (hsCRP), PTX3, MMP-2, MMP-3 and MMP-9 were determined by enzyme-linked immunosorbent assay (ELISA) (SRL, Auburn, NH, USA). Blood levels of these markers were measured in all 45 patients with TA. Plasma levels of PTX3, MMP-2, MMP-9 and hsCRP were also measured in the 20 healthy controls.
Immunohistochemical Staining for PTX3
Formalin-fixed and paraffin embedded tissues of aortic aneurysms were obtained at surgery from 2 female patients (37 and 30 years old, respectively) with TA. As a normal control, formalin-fixed and paraffin embedded tissues of aorta from autopsy of 37-year-old female who died from anaplastic oligodendroglioma. The 4-μm sections were subjected to imunohistochemical staining for PTX3 according to a conventional method. 11 After deparaffinization, sections were incubated with bovine serum albumin, followed by overnight incubation at 4°C with rat antihuman pentaxin-related gene rapidly induced by IL-1β (PTX3) antibody (LifeSpan BioSciences, Seattle, WA, USA). The slides were incubated with biotinylated goat antirat immunoglobulin G secondary antibody (Nichirei, Tokyo, Japan). Sections were visualized with AEC chromogen (Nichirei, Tokyo, Japan) and counterstained with hematoxylin.
Statistical Analyses
Categorical data are presented as numbers (percent), and continuous data as mean ± SD. The 1-way ANOVA with GamesHowel adjustment was used as indicated, and P<0.05 was considered significant. Multiple linear regression was used to assess correlations between variables. Area under the receiving operating characteristics (ROC) curve (AUC) was calculated to determine the diagnostic value and to determine optimal cut-offs. Sensitivity (SE), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) were determined for relevant cut-offs. The analyses involved use of JMP 8.0 for Windows (SAS Institute, Cary, NC, USA).
Results
The patients' characteristics are shown in Table 1 . Patients in the active phase had significantly higher levels of hsCRP, PTX3 and MMP-9 than those in the inactive phase and the normal controls. No difference was found among the groups for serum MMP-2 and MMP-3 levels. As for MMP-9, inactive patients with TA had significantly higher levels than normal controls ( Figure 1 , Table S1 ). Using the ROC curve, we determined the cut-off values for these biomarkers (hsCRP >2,050 ng/ml; PTX3 >5.5 ng/ml; MMP-9 >88 ng/ml) to determine the SE, SP, PPV, NPV and AUC ( Table 2) .
We measured the serum MMP-3 levels before and after starting steroid treatment (daily dose of 20-45 mg) in 9 patients with TA (1 male, 8 females; age 17-25 years), and they rose significantly within 1-2 months in all patients (before 74.6±50.6 vs. after 142.4±84.6 ng/ml, P=0.012), whereas CRP levels dropped (before 7.13±5.20 vs. after 4.70±8.80 mg/dl, P=0.055), concomitant with a dramatic improvement in clinical symptoms (Figure 2) . Based on this result, we examined the relationship between the prednisolone dose and each biomarker. There was a positive correlation between the plasma MMP-3 level and the prednisolone dose. The same relationship was observed with the white blood cell count and prednisolone dose (data not shown). However, PTX3 and MMP-9 levels were not correlated with prednisolone dose (Figure 3) .
Immunohistochemistry of the aortic aneurysm from patients with TA after surgery showed PTX3 expression on the vessel wall. Endothelial cells of the vasa vasorum and inflammatory cells were positive for PTX3 ( Figure 4A ). On the other hand, normal aortic wall did not show inflammatory cell infiltration and the tissue was negative for PTX3 staining ( Figure 4B) . We found that these inflammatory cells were positive for CD11b (Figure S1 ), which was expressed on macrophages and other leukocytes. We also found that inflammatory cells accumulated around the vasa vasorum in the inflammatory lesion were KP-1 positive ( Figure S1 ). Therefore, we concluded that these inflammatory cells, which produced PTX3, were consisted with macrophages.
We followed the serum levels of PTX3 and CRP in several patients who were grouped in the active group to study the time course of these biomarkers in patients with active inflammation. We show the results of a representative case (18-year-old female). The serum CRP level was negative (CRP <0.30 mg/dl) throughout the course with only 1 exception, but the PTX3 level was above the average of the normal controla Sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value (NPV) and area under the curve (AUC) of biomarkers to predict TA activity. Area under the receiving operating characteristics curve was calculated to determine the diagnostic value and to determine optimal cut-offs. SE, SP, PPV, NPV were determined for relevant cut-offs. CI, confidence intervals; hsCRP, high-sensitivity C-reactive protein; PTX3, pentraxin 3; MMP, matrix metalloproteinase; TA, Takayasu arteritis. *P=0.037; **P=0.032. (PTX3=3.09) throughout the observation period ( Figure 5) . We examined the scattergrama of the hsCRP and PTX3 levels, and the hsCRP and MMP-9 levels. Of 28 patients in an active phase, 8 showed a negative hsCRP level (<2,050 ng/ml). Among these patients, the PTX3 and MMP-9 levels were elevated (>5.5 ng/ml, >88 ng/ml, respectively) in 5 patients. In 6 patients without MMP-9 elevation there was high hsCRP. On the other hand, only 2 active patients with low PTX3 levels showed elevated hsCRP levels (Figure 6 ).
Discussion
The etiology of TA is still not fully known, but early diagnosis and early proper treatment have made a better prognosis possible. 12 TA sometimes causes life-threatening vascular complications, including aortic regurgitation, aortic aneurysm, pulmonary hypertension, renal insufficiency and refractory severe systemic hypertension. Without early diagnosis and proper treatment, patients suffer from such symptoms for extended periods. Recent advances in imaging technologies, including MRA, 3D computed tomography and positron emission tomography supported by a CRP elevation, enable us to make an accurate and early TA diagnosis. 10, 13 Recently, we identified a new HLA risk allele useful for diagnosis. 14 Patients usually respond to steroid treatment, but sometimes patients show recurrence of inflammation under proper immunosuppressive treatment. Usually the recurrence can be easily detected using the clinical symptoms and elevation of CRP, but because the majority of such patients usually show a negative CRP before recurrence, it is very difficult to identify the subclinical inflammation in such cases. Also, we have experienced patients who show clinical recurrence without CRP elevation; thus, it is critically important to identify subclinical inflammation to predict subsequent recurrences in patients under immunosuppression therapy. Furthermore, the CRP level increases with inflammation of various organs and tissues, including upper respiratory tract infection, urinary tract infection or oral infection. In such situations it is very difficult to discriminate a recurrence of vasculitis from other causes of inflammation because of the nonspecific CRP elevation. Therefore, biomarkers that detect subclinical vascular inflammation for patients under immunosuppressive treatment are desirable for better patient management.
Against this background, we were interested in PTX3 and the MMPs as better markers for assessing TA activity. These biomarkers are much more specific for arterial inflammation than CRP because of the mechanism of induction and location of production. hsCRP is produced mainly by hepatocytes after simulation with systematically-circulating inflammatory cytokines such as IL-6. PTX3 is produced by local macrophages, dendritic cells, fibroblasts, smooth muscle cells, adipocytes, vascular endothelial cells and neutrophils stimulated by local inflammatory cytokines. 15, 16 MMPs also can be induced in response to cytokines implicated in a variety of inflammatory processes. MMP-2 and MMP-3 are produced mainly by fibroblasts and smooth muscle cells. 17,18 MMP-9 is produced by neutrophils, macrophages and T-lymphocytes. 19 We previously reported that PTX3 could be a new and sensitive biomarker for estimating TA activity and is not affected by the prednisolone dose. 3 This observation had been confirmed by other investigators. 4 We also found that both of PTX3 and MMP-9 were useful biomarkers of active TA in the present study.
The sensitivity and specificity of MMP-9 determination were lower than those of hsCRP and PTX3. The AUC was significantly lower than that of hsCRP and PTX3. However, patients with TA in an inactive stage had significantly higher MMP-9 levels than normal controls. Thus, evaluation of MMP-9 may suggest prior existence of TA even in inactive patients, although the mechanism of this elevation is a matter of further investigation. Also, MMP-9 was not affected by the prednisolone dose.
Matsuyama et al reported that MMP-2 and MMP-3, as well Figure 6 . Scattergrams of hsCRP and PTX3 levels, and hsCRP and MMP-9 levels. 8 of 28 patients in the active phase showed negative hsCRP levels (<2,050 ng/ml). Among these patients, PTX3 and MMP-9 levels were elevated (>5.5 ng/ml, >88 ng/ml, respectively) in 5 patients. Six patients whose MMP-9 levels were negative were detected by hsCRP, whereas only 2 active patients whose PTX3 levels were negative were detected by hsCRP. hsCRP, high-sensitivity C-reactive protein; MMP, matrix metalloproteinase; PTX3, pentraxin3. Multiple Biomarkers for Takayasu Arteritis as MMP-9, could be effective TA biomarkers; 20 however, we could not find any difference in serum MMP-2 and MMP-3 levels between active and inactive patients. The reason for the difference in the results remains unknown. We found that the serum MMP-3 level is affected by the prednisolone dose, but the mechanisms by which steroids increase MMP-3 serum levels remain unknown. 21 Sharif et al observed a doubling of serum MMP-3 levels in patients with rheumatoid arthritis (RA) who were administered 7.5 mg of prednisolone daily, whereas the clinical and biological parameters of RA disease activity decreased with the treatment. 22 Measuring MMP-3 to assess TA disease activity should be done with caution. Among these new biomarkers, PTX3 was the most reliable single marker for several reasons. In 5 of 8 patients included in the active group and having negative hsCRP levels (hsCRP <2,050 ng/ml), PTX3 was positive (PTX3 >5.5 ng/ml). Furthermore, PTX3 is induced by inflammatory stimuli at the local tissue level. We observed PTX3 expression in the aortic lesion of TA patients. The vessel walls of the vasa vasorum, which is a major target for TA inflammation, were strongly positive for PTX3 expression, even though inflammatory infiltration was not remarkable in these sections. 7 A histological feature of TA is hyperplasia and inflammation of the vasa vasorum. Our immunohistochemical study indicated that PTX3 was strongly expressed on the infiltrating inflammatory cells, especially CD11b and KP-1 positive macrophages. These observations suggest that subtle inflammatory changes in the small arteries of the vessel wall cause PTX3 expression. Examination of scattergrams of PTX3 and hsCRP suggested that PTX3 is able to detect active patients who could not detected by hsCRP (Figure 6 ). This evidence indicates that PTX3 could be a better biomarker for assessing TA activity than hsCRP.
The PTX3 level is not affected by prednisolone. Considering the need for prednisolone in patients with TA, this evidence is very important for managing TA patients.
Study Limitations
We could follow the time course changes in these biomarkers in only selected patients. Furthermore, the size of this study is limited and the length of follow-up for these patients might not be enough. Also, the influence of immunosuppressants should be evaluated further. As for the histological examinations, it is very difficult to obtain these materials from TA patients. More importantly, the relationship between the long-or midterm prognosis and the levels of these biomarkers should be a matter of investigation, although it takes many years.
